{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Akt/GSK3\u03b2/\u03b2-catenin signaling pathways", "SAR", "furocoumarin", "melanogenesis", "molecular docking", "p38 MAPK", "vitiligo"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35887323", "DateCompleted": {"Year": "2022", "Month": "07", "Day": "28"}, "DateRevised": {"Year": "2022", "Month": "07", "Day": "31"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "07", "Day": "19"}], "Language": ["eng"], "ELocationID": ["7959", "10.3390/ijms23147959"], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "23", "Issue": "14", "PubDate": {"Year": "2022", "Month": "Jul", "Day": "19"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "Study of Novel Furocoumarin Derivatives on Anti-Vitiligo Activity, Molecular Docking and Mechanism of Action.", "Abstract": {"AbstractText": ["Vitiligo is a common chronic dermatological abnormality that afflicts tens of millions of people. Furocoumarins isolated from Uygur traditional medicinal material <i>Psoralen corylifolia</i> L. have been proven to be highly effective for the treatment of vitiligo. Although many furocoumarin derivatives with anti-vitiligo activity have been synthesized, their targets with respect to the disease are still ambiguous. Fortunately, the JAKs were identified as potential targets for the disease and its inhibitors have been proved to be effective in the treatment of vitiligo in many clinical trials. Thus, sixty-five benzene sulfonate and benzoate derivatives of furocoumarins (<b>7a</b>-<b>7ad</b>, <b>8a</b>-<b>8ag</b>) with superior anti-vitiligo activity targeting JAKs were designed and synthesized based on preliminary research. The SAR was characterized after the anti-vitiligo-activity evaluation in B16 cells. Twenty-two derivatives showed more potent effects on melanin synthesis in B16 cells than the positive control (8-MOP). Among them, compounds <b>7y</b> and <b>8</b> not only could increase melanin content, but they also improved the catecholase activity of tyrosinase in a concentration-dependent manner. The docking studies indicated that they were able to interact with amino acid residues in JAK1 and JAK2 via hydrogen bonds. Furthermore, candidate <b>8</b> showed a moderate inhibition of CXCL-10, which plays an important role in JAK-STAT signaling. The RT-PCR and Western blotting analyses illustrated that compounds <b>7y</b> and <b>8</b> promoted melanogenesis by activating the p38 MAPK and Akt/GSK-3\u03b2/\u03b2-catenin pathways, as well as increasing the expressions of the MITF and tyrosinase-family genes. Finally, furocoumarin derivative <b>8</b> was recognized as a promising candidate for the fight against the disease and worthy of further research <i>in vivo</i>."]}, "AuthorList": [{"Identifier": ["0000-0001-5943-6771"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization, CAS Key Labortory of Chemistry of Plant Resources in Arid Zone, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Urumqi 830011, China."}, {"Identifier": [], "Affiliation": "University of Chinese Academy of Sciences, Beijing 100049, China."}], "LastName": "Niu", "ForeName": "Chao", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization, CAS Key Labortory of Chemistry of Plant Resources in Arid Zone, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Urumqi 830011, China."}], "LastName": "Zang", "ForeName": "Deng", "Initials": "D"}, {"Identifier": ["0000-0003-4652-6879"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization, CAS Key Labortory of Chemistry of Plant Resources in Arid Zone, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Urumqi 830011, China."}, {"Identifier": [], "Affiliation": "University of Chinese Academy of Sciences, Beijing 100049, China."}], "LastName": "Aisa", "ForeName": "Haji Akber", "Initials": "HA"}], "GrantList": [{"GrantID": "2019425", "Agency": "Chinese Academy of Sciences", "Country": ""}, {"GrantID": "2021-JCTD-001", "Agency": "Chinese Academy of Sciences", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Furocoumarins"}, {"RegistryNumber": "0", "NameOfSubstance": "Melanins"}, {"RegistryNumber": "EC 1.14.18.1", "NameOfSubstance": "Monophenol Monooxygenase"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "Glycogen Synthase Kinase 3 beta"}], "MeshHeadingList": [{"QualifierName": ["chemistry"], "DescriptorName": "Furocoumarins"}, {"QualifierName": [], "DescriptorName": "Glycogen Synthase Kinase 3 beta"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["metabolism"], "DescriptorName": "Melanins"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": ["metabolism"], "DescriptorName": "Monophenol Monooxygenase"}, {"QualifierName": ["metabolism"], "DescriptorName": "Vitiligo"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Ezzedine K., Sheth V., Rodrigues M., Eleftheriadou V., Harris J.E., Hamzavi I.H., Pandya A.G. Vitiligo is not a cosmetic disease. J. Am. Acad. Dermatol. 2015;73:883\u2013885. doi: 10.1016/j.jaad.2015.07.039.", "ArticleIdList": ["10.1016/j.jaad.2015.07.039", "26475548"]}, {"Citation": "Sheth V.M., Gunasekera N.S., Silwal S., Qureshi A.A. Development and pilot testing of a vitiligo screening tool. Arch. Dermatol. Res. 2015;307:31\u201338. doi: 10.1007/s00403-014-1515-1.", "ArticleIdList": ["10.1007/s00403-014-1515-1", "25361870"]}, {"Citation": "Alikhan A., Felsten L.M., Daly M., Petronic-Rosic V. Vitiligo: A comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J. Am. Acad. Dermatol. 2011;65:473\u2013491. doi: 10.1016/j.jaad.2010.11.061.", "ArticleIdList": ["10.1016/j.jaad.2010.11.061", "21839315"]}, {"Citation": "Lotti T., Zanardelli M., D\u2019Erme A.M. Vitiligo: What\u2019s new in the psycho-neuro-endocrine-immune connection and related treatments. Wien. Med. Wochenschr. 2014;164:278\u2013285. doi: 10.1007/s10354-014-0288-7.", "ArticleIdList": ["10.1007/s10354-014-0288-7", "25059737"]}, {"Citation": "Rork J.F., Rashighi M., Harris J.E. Understanding autoimmunity of vitiligo and alopecia areata. Curr. Opin. Pediatr. 2016;28:463\u2013469. doi: 10.1097/MOP.0000000000000375.", "ArticleIdList": ["10.1097/MOP.0000000000000375", "PMC4957563", "27191524"]}, {"Citation": "Wang Y., Li S., Li C. Perspectives of New Advances in the Pathogenesis of Vitiligo: From Oxidative Stress to Autoimmunity. Med. Sci. Monit. 2019;25:1017\u20131023. doi: 10.12659/MSM.914898.", "ArticleIdList": ["10.12659/MSM.914898", "PMC6373225", "30723188"]}, {"Citation": "Rosmarin D., Pandya A.G., Lebwohl M., Grimes P., Hamzavi I., Gottlieb A.B., Butler K., Kuo F., Sun K., Ji T., et al. Ruxolitinib cream for treatment of vitiligo: A randomised, controlled, phase 2 trial. Lancet. 2020;396:110\u2013120. doi: 10.1016/S0140-6736(20)30609-7.", "ArticleIdList": ["10.1016/S0140-6736(20)30609-7", "32653055"]}, {"Citation": "Namazi M.R. Neurogenic dysregulation, oxidative stress, autoimmunity, and melanocytorrhagy in vitiligo: Can they be interconnected? Pigment Cell Res. 2007;20:360\u2013363. doi: 10.1111/j.1600-0749.2007.00408.x.", "ArticleIdList": ["10.1111/j.1600-0749.2007.00408.x", "17850509"]}, {"Citation": "Ralf Paus L., Schallreuter K.U., Bahadoran P., Picardo M., Slominski A., Elassiuty Y.E., Kemp E.H., Giachino C., Liu J.B., Luiten R.M., et al. Vitiligo pathogenesis: Autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp. Dermatol. 2008;17:139\u2013140. doi: 10.1111/j.1600-0625.2007.00666_1.x.", "ArticleIdList": ["10.1111/j.1600-0625.2007.00666_1.x", "18205713"]}, {"Citation": "Marmol V., Beermann F. Tyrosinase and related proteins in mammalian pigmentation. FEBS Lett. 1996;381:165\u2013168. doi: 10.1016/0014-5793(96)00109-3.", "ArticleIdList": ["10.1016/0014-5793(96)00109-3", "8601447"]}, {"Citation": "Land E.J., Ramsden C.A., Riley P.A. Quinone Chemistry and Melanogenesis. Methods Enzymol. 2004;378:88\u2013109.", "ArticleIdList": ["15038959"]}, {"Citation": "Schallreuter K.U., Kothari S., Chavan B., Spencer J.D. Regulation of melanogenesis\u2014Controversies and new concepts. Exp. Dermatol. 2008;17:395\u2013404. doi: 10.1111/j.1600-0625.2007.00675.x.", "ArticleIdList": ["10.1111/j.1600-0625.2007.00675.x", "18177348"]}, {"Citation": "Levy C., Khaled M., Fisher D.E. MITF: Master regulator of melanocyte development and melanoma oncogene. Trends Mol Med. 2006;12:406\u2013414. doi: 10.1016/j.molmed.2006.07.008.", "ArticleIdList": ["10.1016/j.molmed.2006.07.008", "16899407"]}, {"Citation": "Tsang T.F., Ye Y., Tai W.C., Chou G., Leung A.K., Yu Z., Hsiao W. Inhibition of the p38 and PKA signaling pathways is associated with the anti-melanogenic activity of Qian-wang-hong-bai-san, A Chinese herbal formula, in B16 cells. J. Ethnopharmacol. 2012;141:622\u2013628. doi: 10.1016/j.jep.2011.08.043.", "ArticleIdList": ["10.1016/j.jep.2011.08.043", "21903156"]}, {"Citation": "Bentley N.J., Eisen T., Goding C.R. Melanocyte-specific expression of the human tyrosinase promoter: Activation by the microphthalmia gene product and role of the initiator. Mol. Cell. Biol. 1994;14:7996\u20138006. doi: 10.1128/MCB.14.12.7996-8006.1994.", "ArticleIdList": ["10.1128/MCB.14.12.7996-8006.1994", "PMC359338", "7969139"]}, {"Citation": "Liu J.J., Fisher D.E. Lighting a path to pigmentation: Mechanisms of MITF induction by UV. Pigment Cell Melanoma Res. 2010;23:741\u2013745. doi: 10.1111/j.1755-148X.2010.00775.x.", "ArticleIdList": ["10.1111/j.1755-148X.2010.00775.x", "20973930"]}, {"Citation": "Pillaiyar T., Manickam M., Jung S.H. Downregulation of melanogenesis: Drug discovery and therapeutic options. Drug Discov. Today. 2017;22:282\u2013298. doi: 10.1016/j.drudis.2016.09.016.", "ArticleIdList": ["10.1016/j.drudis.2016.09.016", "27693716"]}, {"Citation": "Villarino A.V., Kanno Y., O\u2019Shea J.J. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat. Immunol. 2017;18:374\u2013384. doi: 10.1038/ni.3691.", "ArticleIdList": ["10.1038/ni.3691", "28323260"]}, {"Citation": "Howell M.D., Kuo F.I., Smith P.A. Targeting the janus kinase family in autoimmune skin diseases. Front. Immunol. 2019;10:2342. doi: 10.3389/fimmu.2019.02342.", "ArticleIdList": ["10.3389/fimmu.2019.02342", "PMC6794457", "31649667"]}, {"Citation": "Shreberk-Hassidim R., Ramot Y., Zlotogorski A. Janus kinase inhibitors in dermatology: A systematic review. J. Am. Acad. Dermatol. 2017;76:745\u2013753. doi: 10.1016/j.jaad.2016.12.004.", "ArticleIdList": ["10.1016/j.jaad.2016.12.004", "28169015"]}, {"Citation": "Schwartz D.M., Kanno Y., Villarino A., Ward M., Gadina M., O\u2019Shea J.J. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov. 2017;16:843\u2013862. doi: 10.1038/nrd.2017.201.", "ArticleIdList": ["10.1038/nrd.2017.201", "29104284"]}, {"Citation": "Cinats A., Heck E., Robertson L. Janus Kinase Inhibitors: A Review of their emerging applications in dermatology. Skin Ther. Lett. 2018;23:5\u20139.", "ArticleIdList": ["29772037"]}, {"Citation": "Craiglow B.G., King B.A. Tofacitinib citrate for the treatment of vitiligo: A pathogenesis-directed therapy. JAMA Dermatol. 2015;151:1110\u20131112. doi: 10.1001/jamadermatol.2015.1520.", "ArticleIdList": ["10.1001/jamadermatol.2015.1520", "26107994"]}, {"Citation": "Liu L.Y., Strassner J.P., Refat M.A., Harris J.E., King B.A. Repigmentation invitiligousing the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J. Am. Acad. Dermatol. 2017;77:675\u2013682. doi: 10.1016/j.jaad.2017.05.043.", "ArticleIdList": ["10.1016/j.jaad.2017.05.043", "PMC6233876", "28823882"]}, {"Citation": "Joshipura D., Alomran A., Zancanaro P., Rosmarin D. Treatment ofvitiligowith the topical Janus kinase inhibitorruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B. J. Am. Acad. Dermatol. 2018;78:1205\u20131207. doi: 10.1016/j.jaad.2018.02.023.", "ArticleIdList": ["10.1016/j.jaad.2018.02.023", "29438765"]}, {"Citation": "Rothstein B., Joshipura D., Saraiya A., Abdat R., Ashkar H., Turkowski Y., Sheth V., Huang V., Au S.C., Kachuk C., et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J. Am. Acad. Dermatol. 2017;76:1054\u20131060. doi: 10.1016/j.jaad.2017.02.049.", "ArticleIdList": ["10.1016/j.jaad.2017.02.049", "28390737"]}, {"Citation": "Harris J.E., Rashighi M., Nguyen N., Jabbari A., Ulerio G., Clynes R., Christiano A.M., Mackay-Wiggan J. Rapid skin repigmentationon oral ruxolitinib in a patient with coexistent vitiligoand alopecia areata (AA) J. Am. Acad. Dermatol. 2016;74:370\u2013371. doi: 10.1016/j.jaad.2015.09.073.", "ArticleIdList": ["10.1016/j.jaad.2015.09.073", "PMC4718770", "26685721"]}, {"Citation": "Xiao B.H., Wu Y., Sun Y., Chen H.D., Gao X.H. Treatment of vitiligo with NB-UVB: A systematic review. J. Dermatolog. Treat. 2015;26:340\u2013346. doi: 10.3109/09546634.2014.952610.", "ArticleIdList": ["10.3109/09546634.2014.952610", "25102894"]}, {"Citation": "Esmat S., Hegazy R.A., Shalaby S., Hu S.C., Lan C.E. Phototherapy and combination therapies for vitiligo. Dermatol. Clin. 2017;35:171\u2013192. doi: 10.1016/j.det.2016.11.008.", "ArticleIdList": ["10.1016/j.det.2016.11.008", "28317527"]}, {"Citation": "Gaudino E.C., Tagliapietra S., Martina K., Palmisanob G., Cravotto G. Recent advances and perspectives in the synthesis of bioactive coumarins. RSC Adv. 2016;6:46394\u201346405. doi: 10.1039/C6RA07071J.", "ArticleIdList": ["10.1039/C6RA07071J"]}, {"Citation": "Roskoski R., Jr. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol. Res. 2016;111:784\u2013803. doi: 10.1016/j.phrs.2016.07.038.", "ArticleIdList": ["10.1016/j.phrs.2016.07.038", "27473820"]}, {"Citation": "Frisoli M.L., Essien K., Harris J.E. Vitiligo: Mechanisms of Pathogenesis and Treatment. Annu. Rev. Immunol. 2020;38:621\u2013648. doi: 10.1146/annurev-immunol-100919-023531.", "ArticleIdList": ["10.1146/annurev-immunol-100919-023531", "32017656"]}, {"Citation": "Fensome A., Ambler C.M., Arnold E., Banker M.E., Brown M.F., Chrencik J., Clark J.D., Dowty M.E., Efremov I.V., Flick A., et al. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841) J. Med. Chem. 2018;61:8597\u20138612. doi: 10.1021/acs.jmedchem.8b00917.", "ArticleIdList": ["10.1021/acs.jmedchem.8b00917", "30113844"]}, {"Citation": "Davis R.R., Li B., Yun S.Y., Chan A., Nareddy P., Gunawan S., Ayaz M., Lawrence H.R., Reuther G.W., Lawrence N.J., et al. Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof. J. Med. Chem. 2021;64:2228\u20132241. doi: 10.1021/acs.jmedchem.0c01952.", "ArticleIdList": ["10.1021/acs.jmedchem.0c01952", "PMC8327781", "33570945"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "6", "Day": "6"}, {"Year": "2022", "Month": "7", "Day": "8"}, {"Year": "2022", "Month": "7", "Day": "13"}, {"Year": "2022", "Month": "7", "Day": "27", "Hour": "1", "Minute": "24"}, {"Year": "2022", "Month": "7", "Day": "28", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "7", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "7", "Day": "19"}], "PublicationStatus": "epublish", "ArticleIdList": ["35887323", "PMC9316487", "10.3390/ijms23147959", "ijms23147959"]}}], "PubmedBookArticle": []}